Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA V: Final Recommendations Fund Proposals In Two Of Three Tiers

Executive Summary

Industry and FDA agreed to a recommendation package for the PDUFA V commitment letter after dividing agency proposals into three tiers and funding two.

Related Content

PDUFA VI: Innovative Trial Design Proposal Includes Modeling, Simulation
PDUFA VI: FDA Proposes Expanding Sentinel, Real-World Safety Data Sources
Separate FDA Safety Office Attached To House Report, Still Faces Steep Road
Biosimilars: FDA Trying Group-Think Negotiating Strategy For User Fee
Pre-NDA Work Takes Added Importance As PDUFA V Stretches Review Cycle
PDUFA Proposal Sheds Tier 3 Funding
PDUFA V Agreement Appears Set Between FDA And Industry
PDUFA Formula Could Better Incorporate Present Economic Conditions
PDUFA Needs Mid-Cycle Correction System As Part Of Reauthorization, Industry Says
PDUFA V: FDA Relaxes Pre-Submission Meeting Requirement





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts